Cyclosporine A exhibits its effect by modulating the immune system, which can be a double-edged sword in the context of cancer. On one hand, it can suppress the immune system, potentially allowing cancer cells to proliferate unchecked. On the other hand, it can inhibit the activity of multidrug resistance proteins like P-glycoprotein, which cancer cells often exploit to evade chemotherapy. This duality makes Cyclosporine A a subject of ongoing research in oncology.
